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The combination of high-intensity focused ultrasound (HIFU) and transarterial chemoembolization (TACE) has been
experimentally performed in a variety ofmalignant tumors, and its validity has not yet been evaluated for hepatoblastoma
(HB). We evaluated the disease-response rate, resection rate, and toxicity in children with unresectable or metastatic HB
(stage III and stage IVHB) after sequential treatmentwith TACE plusHIFU in a controlled clinical trial. The 35 patientswith
unresectable or metastatic HB were nonrandomly assigned to HIFU ablation (n = 12) or C5V chemotherapy (n = 23).
The rates of complete resection, tumor response, and treatment toxicitywere evaluated for both regimens. Nine patients
who received C5V and 10 patients who received TACE plus HIFU became operable (P = .02). The 3-year event-free
survival and overall survival rates were 43.03% and 56.68% in the C5V group and 38.57% and 57.86% in the TACE plus
HIFUgroup, respectively. Acutegrade3or 4 adverseevents, includingneutropenia, thrombocytopenia, andanemia,were
more frequent in patients treated with C5V therapy than in patients receiving TACE plus HIFU. HIFU ablation achieved a
higher rate of complete resection and a lower rate of severe complications comparedwith C5V treatment in childrenwith
advanced HB (Chinese Clinical Trials Registry No. ChiCTR-PRCH-08000182).
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Hepatoblastoma (HB) is the most common pediatric primary liver
malignancy. The curative therapy for HB requires surgical resection.
However, only half of newly diagnosed patients can be treated with
surgery at initial presentation [1,2]. Metastatic and unresectable disease
at diagnosis portends an extremely poor prognosis, and patients rarely
achieve long-term survival with chemotherapy and aggressive surgical
resection of all tumor sites [3,4]. Several clinical trials have shown that
systemic chemotherapy effectively improves response and survival of
patients with unresectable andmetastatic HB by reducing the incidence
of local recurrence and ultimately increasing tumor resectability [5,6].
However, systemic therapy increases toxicity, and systemic chemother-
apy regimensmust be stopped due to adverse events such as neutropenia
and nephrotoxicity [7,8]. Previous studies have shown that the event-
free survival (EFS) of patients with unresectable disease remains
Figure 1. Flow diagram of the enrollment, treatment, and outcome
of the 35 patients with HB. *Six patients with TACE plus HIFU
ablation and four patients treated with C5V refused surgery to
remove the residual tumor.
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metastatic disease is also unsatisfactory [9,10], and the relative resistance
of this neoplasm to present therapeutic regimens suggests that new
treatment approaches are required. It is possible that the current strategy
of treatment must be redesigned.
High-intensity focused ultrasound (HIFU) is an extracorporeal
method used to treat primary solid tumors and metastatic disease
[11–13]. Compared with conventional therapies, HIFU significantly
reduces local, regional, and systemic side effects and provides
additional therapeutic options in cases when conventional therapies
fail [14,15]. Extracorporeal Magnetic Resonance (MR)-guided HIFU
devices have been approved by the Food and Drug Administration
(FDA) in the United States for the clinical treatment of uterine
fibroids, and ultrasound-guided HIFU devices have also been used in
Europe to treat both benign and malignant tumors after obtaining
Conformite Europeenne (CE) approval [16,17].
Transarterial chemoembolization (TACE) is a widely used treatment
for patients with large-volume solid tumors. TACE is usually used in
combination with ablative therapies to exterminate residual tumor cells
[18]. HIFU combined with TACE has been used empirically for many
years, and a small number of retrospective, uncontrolled reports suggest
benefits of this therapy [19].We previously performedHIFU combined
with TACE to treat unresectable disease, including HB, at our institute
[19]. In the current study, chemotherapy and TACE plus HIFU
regimens were nonrandomly compared in patients with stage III and
stage IV HB. Herein, we report the clinical features, tumor response,
adverse events, and treatment outcomes for a cohort of patients from
our institute with advanced pediatric HB treated by these regimens.
Materials and Methods
Patients
From August 2006 to November 2011, there are 45 children with
stage III and stage IV HB diagnosed in our institute. The patients were
eligible for study inclusion if they were younger than 5 years old at
diagnosis and had biopsy-proven HB that was either unresectable or
metastatic at presentation and previously untreated. Among them, 10
cases were excluded because of lost to follow-up and more than 5 years
old. The remaining 35 cases were included in this study. TheTACE plus
HIFU ablation in our institute was initiated in March 2009, and 12
patients received HIFU and TACE treatment protocols. For chemo-
therapy, 23 patients were included from August 2006 to November
2011. A determination of serum alpha-fetoprotein (AFP) concentration
values was mandatory at diagnosis. Human investigations were
performed after approval by the Human Investigations Committee of
ChongqingMedical University and in accordance with an assurance filed
with and approved by the Department of Health andHuman Services of
Chongqing Medical University. Open or closed surgical biopsy was also
mandatory for obtaining an accurate diagnosis before chemotherapy,
except for patients inwhom the surgical risk was considered unacceptable
and unequivocal clinical findings had already been obtained (HB-
compatible images and an elevated AFP level). The pretreatment
assessment of the primary tumor was performed using abdominal
ultrasonography and computed tomography (CT) with contrast
medium, magnetic resonance imaging with contrast enhancement,
or both methods. The presence of lung metastases was assessed by a
chest X-ray (posteroanterior and lateral views) and lung CT scan.
Infants with pure fetal HB at the initial biopsy were excluded
because these tumors appear to have a different biology [20].Study Design
The study design details and requirements are described in
Figure 1. After the diagnosis of HB, patients initially received two
cycles of a modified C5V regimen (cisplatin: 100 mg/m2 per dose
D1; 5-fluorouracil: 600 mg/m2 per dose D3; vincristine: 1.5 mg/m2
per dose D3) at 21-day intervals. Patients were then reevaluated for
response and surgical resection after two courses of chemotherapy. If
the tumor was considered to be unresectable, then the patients were
divided to two treatment groups: the control group (n = 23), in which
further four cycles of C5V chemotherapy were performed, and the
TACE plus HIFU group (n = 12), which was suggested to undergo
TACE plus HIFU ablation. A detailed description of the TACE plus
HIFU treatment procedure was provided by Wang et al. [19] After
the TACE plus HIFU treatments were completed, four C5V cycles
were administered. Thus, each patient was scheduled to receive a
maximum of six cycles of the C5V regimen.
TACE Procedures
TACE was performed in all patients before HIFU ablation.
Depending on the tumor size, location, and arterial supply and its
satellite lesions, the tumor-feeding arteries were selectively embolized
using a 3-F to 5-F tracker catheter. Either 100 mg/m2 of carboplatin
(Qilu Pharmaceutical Factory, Jinan, China) or 10 to 15 mg/m2 of
adriamycin (Pfizer, Nerviano, Italy) was mixed in 3 to 8 ml of iodized
oil (Lipiodol; Huaihai Pharmaceutical Factory, Shanghai, China), and
the mixed suspension was slowly injected into the tumor-feeding
arteries with fluoroscopic guidance. Embolization of the feeding
arteries of all tumors was performed with the use of a 1 mm × 1 mm ×
10 mm gelatin sponge (Gelfoam; 3rd Pharmaceutical Factory of Nanjing,
Nanjing, China) in all patients after injecting the embolization suspension.
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HIFU ablation procedure was performed 2 to 3 weeks after TACE.
The Model-JC 200 HIFU System [Chongqing Haifu (HIFU) Tech
Co, Ltd, Chongqing, China] was used in all cases and has been
described previously [19]. Briefly, the device consisted of a 12-cm
diameter, single-element, piezo-ceramic transducer with acoustic
lenses of varying focal lengths, driven at 0.8 MHz to produce
therapeutic ultrasound energy, and an ultrasound imaging device
(Esaote DU3, Genova, Italy) mounted to guide the transducer in real
time. After general anesthesia was induced, the patient was accurately
positioned to put the targeted lesion in contact with the degassed
water. The coaxial US imaging device was used to establish three-
dimensional images of the entire tumor, and the target tumor was
divided into parallel slices of 5-mm separation. Then, with movement
of the integrated transducer, the tumor was completely ablated from
the deep to shallow regions and repeated section by section to achieve
entire tumor ablation. Dependent on the size of targeted tumors,
HIFU exposure time varied from 30 to 202 min and acoustic power
ranged from 181 to 256 W. There was no second HIFU ablation
performed in this series.
Follow-Up Response Evaluation
Serum AFP levels and appropriate imaging studies, including CT
of the chest and abdomen, were performed before therapy and after
every additional cycle of chemotherapy. The tests were then repeated
to monitor the disease every 2 months for 2 years and then every 3
months for 2 years. After 2 years, the tests were repeated annually.
The tumor response was assessed using the Response Evaluation
Criteria in Solid Tumors version 1.1. Complete resection was defined
as resection of all tumor sites on the basis of surgical findings and
postsurgical images. Any patient who died was considered to have
experienced an overall survival (OS) event, regardless of the cause of
death. The patients who did not experience an event were censored
on the date of last contact.
Treatment Toxicity
Patients were monitored weekly by physical examination, complete
blood cell counts, and liver function tests. Approximately 1 month
after completion of HIFU, the patients were evaluated by physical
examination, blood chemistry analysis, and CT. A follow-up was
performed monthly by telephone interviews with patients after
HIFU. The acute toxicities associated with combined treatment were
graded using the National Cancer Institute Common Toxicity
Criteria version 3.0. The individual incidents of various toxicities
were graded on a scale of 1 to 4, according to common toxicity
criteria. Severe acute toxicity was defined as grade 3 or 4 infection,
stomatitis, febrile neutropenia, or all of these events according to the
National Cancer Institute Common Toxicity Criteria. The limits for
toxicity grades depended on both patient age and the particular organ
system involved.IV 8 3 .71 *
Tumor diameter (cm) 9.4 11.3 .52 †
Multifocal tumors (n) 4 5 .20 *
Serum AFP (ng/ml) 11369 8917 .64 †
Lung metastases (n) 7 5 .71 *
Vascular involvement (n) 5 0 .14 *
Histology (n)
Embryonal 4 2 1.00 *
Mixed epithelial (fetal/embryonal) and mesenchymal 17 8 .71 *
Small cell 2 2 .59 *
* Fisher exact test.
† Unpaired t test.Statistical Methods
The statistical analysis was conducted with current data as
of December 2012. We reviewed the post-recurrence or post-
progression outcome of patients to elucidate the role of HIFU. The
ratio differences between the two treatment regimens were analyzed
using Fisher exact test. The statistical significance of any observed
difference between the mean values of the control and treatment
groups was evaluated with an unpaired Student’s t test. We alsoreviewed the outcomes (EFS) of patients according to their treatment
assignment. The Kaplan-Meier method was used to estimate survival
curves, and the difference between the treatment and control groups
was evaluated using a log-rank test. All data were analyzed by three
investigators. All statistical procedures were performed using
GraphPad Prism software (San Diego, CA).
Results
Patient and Tumor Characteristics
At the time of analysis, the intention-to-treat sample consisted of
the 45 eligible and evaluable patients. Ten patients were excluded
from the study because they lacked proper documentation. Sixty-six
percent (n = 23) of patients were assigned to receive C5V, whereas
34% (n = 12) of patients were assigned to receive TACE plus HIFU.
Six patients without response to the initial course of chemotherapy
were treated with TACE plus HIFU ablation by recommendation.
Six patients were treated with TACE plus HIFU ablation due to
parental request. Tumor staging revealed that stage III (9 of 12, 75%,
C5V patients and 15 of 23, 65.2%, TACE plus HIFU patients) was
more common than stage IV disease. The male-to-female ratio was
2.3:1 in the C5V treatment group and 2:1 in the TACE plus HIFU
treatment group. The patient ages ranged from 3 months to 4 years.
The tumor diameters varied from 6.1 to 19.3 cm (median, 9.4 cm for
C5V and 11.3 cm for TACE plus HIFU). Multifocal tumors were
present in nine patients, five of whom were treated with TACE plus
HIFU (55.5%). Within this group, two patients showed diffuse liver
involvement with no healthy hepatic parenchyma visible on CT.
Vascular involvement (hepatic veins, vena cava, and/or both branches
of the portal vein) was present in five cases (all C5V). A tumor biopsy
was performed at diagnosis in 34 of 35 cases (open biopsy in 12 and
closed biopsy in 23). The pathologic diagnosis was determined by
examination of the tissue submitted to the pathologists. Most tumors
were classified as mixed epithelial and mesenchymal histologic
variants of HB (25 of 35; 71.4%). Six of the 35 tumors were classified
as embryonal-type tumors, and the remaining tumors (n = 4) had
mixed epithelial (fetal, embryonal) or small cell histology. Table 1
describes the clinical and demographic characteristics and disease
staging of patients with HB based on their treatment assignment.
There were no significant differences in the distributions of any of
these characteristics between the two regimens.
Table 2. Grade 3 or 4 Toxicity according to Treatment Regimen








HIFU (n = 12)
P *
Neutropenia 23 0 .03 11 0 .006
Infection 14 1 .70 5 1 .64
Mucositis 2 0 1.00 1 0 1.00
Thrombocytopenia 12 0 .35 6 0 .07
Anemia 19 0 .06 10 0 .007
Renal and cardiac toxicity 3 0 1.00 2 0 .54
* Fisher exact test.
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Compared with the conventional chemotherapy for HB, patients
treated with TACE plus HIFU ablation exhibited a lower rate of major
complications. The HIFU procedure was well tolerated. Table 2
describes the most common toxicities associated with these regimens.
Twenty-eight (80%) of the 35 eligible patients experienced an event
while in the hospital. The overall toxicities, including infection,
neutropenia, thrombocytopenia, anemia, stomatitis, adverse cardiac
effects, ototoxicity, and nephrotoxicity, were more frequent in patients
who received chemotherapy than in patients treated with TACE plus
HIFU (Table 2). The combination of TACE plus HIFU ablation
caused a transient disturbance of physiological and biochemical values.
Among the patients with available data, there were transient bilirubin
increases in two patients after TACE plusHIFU ablation. The bilirubin
stabilized in both patients at day 14. There was also a transient
insignificant drop in hemoglobin and an increase in white blood cell
count immediately after HIFU ablation. The aspartate transaminase
(AST), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH)
increased transiently after treatment in some patients, which is
consistent with a small volume of hepatic cellular destruction.
Tumor Response
According to the Response Evaluation Criteria in Solid Tumors, the
1-month post-treatment evaluation showed that the response rate was
91.7% in the TACE plusHIFU group and 82.6% in the chemotherapy
group (Table 3). Of the 12 patients with the TACE plus HIFU
treatments, a complete response was observed in 10 (83.3%) of the 12
patients, and the AFP level decreased to normal in these patients.
Disease progression occurred in one (8.3%) patient 3 months after
HIFU ablation. In the C5V group, 19 patients (82.6%) exhibited
partial responses to the treatment, while 2 patients (8.7%) had stable
disease and 2 patients (8.7%) had progressive disease. Seven patients




HIFU (n = 12)
P Odds Ratio (95% CI)
Complete response (n) 0 10 .0001 * 0.003 (0.0001-0.08)
Partial response (n) 19 1 .0001 * 52.25 (5.164-528.6)
Stable disease (n) 2 0 .54 *
Progressive disease (n) 2 1 1.00 *
Operability (n, %) 9 10 .02 0.129 (0.023-0.728)
Tumor excision (n) 7 4 1.00
TPN (n) 12 0 .002 * 27.17 (1.438-513.3)
Duration of hospitalization (days) 14.3 ± 5.4 9.3 ± 3.3 .01 †
* Fisher exact test.
† Unpaired t test.had a complete response of the lung lesions, and three patients had
partial responses. Three patients exhibited progressive disease.
One patient had local tumor progression without distant metastasis,
and one patient had bone metastasis without local progression (C5V).
The remaining patient had lung metastasis without local progression
(TACE plus HIFU). For one patient who was lost to follow-up, data on
tumor response were missing.
The tumor sizes were gradually reduced by 1month after TACE plus
HIFU ablation. The tumor sizes at 1, 3, 6, and 12 months after the
initial treatment in both groups are shown in Figure 2A. The tumor size
reductions in the TACE plus HIFU group were significantly greater
than those in the C5V group at each follow-up interval (P b .01).Figure 2. (A) The reduction in tumor volumes in patients treated with
C5V or HIFU plus TACE was measured with Doppler US at the
indicated follow-up day (*P b .001, unpaired Student’s t test).
(B) Kaplan-Meier curves for EFS [C5V vsTACEplusHIFU,P= .85, log-
rank (Mantel-Cox) test]. (C) Kaplan-Meier curves for overall survival
[C5V vs TACE plus HIFU, P = .86, log rank (Mantel-Cox) test].
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alimentation (TPN), whereas the C5V patients required 25 to 87
TPN cycles (12 of 23 patients, P b .01). Similarly, the duration of
hospitalization was significantly longer for patients treated with C5V
compared with patients treated with TACE plus HIFU (P b .01).
Survival
The median follow-up time for EFS was 3.7 years (range, 1.1-6.4
years). The 3-year EFS was similar between the two regimens. The 3-
year EFS was 51% (90% Confidence Interval [CI], 27 to 49%) in the
TACE plus HIFU patient group and 49% (90% CI, 51 to 68%) in
the C5V chemotherapy group (P = .855; Figure 2B). The risk of
death in patients initially enrolled in the TACE plus HIFU group was
similar to that in patients receiving C5V. The estimated 3-year overall
survival was 68% for patients initially treated with HIFU and 63%
for patients treated with C5V (P = .865; Figure 2C).
Surgical Features
The post-treatment assessment of the operability of the primary
tumor by our surgical group showed that following HIFU ablation,
83% (10 of 12) of patients were eventually eligible for tumor
resection, which is statistically superior to the eligibility rate (9 of 23)
in the C5V chemotherapy group (P = .02). In 16 cases of HB
(45.7%), primary tumors were not operable because of extensive liver
involvement. Complete resection of all tumor lesions was eventually
achieved in 11 patients (including four TACE plus HIFU patients
and seven C5V chemotherapy patients). The following types of liver
resection were performed: 1) seven right and left hemihepatectomies
and (2) three extended hemihepatectomies. For one patient, he
suffered from HB metastasis to the lung and received the right
hemihepatectomy and lateral lobectomy. In one patient of extensive
liver involvement, primary tumor never became operable. One
patient died of postoperative bleeding complications. All 10 children
with complete tumor resection experienced complete remission.
Disease Progression, Relapse, and Death
Eighteen patients exhibited recurrence or progressive disease
during the follow-up, namely 6 patients in the TACE plus HIFU
group (6 of 12, 50%) and 12 patients in the chemotherapy group (12
of 23, 52.2%; Table 4). The relapses occurred 6 to 46 months after
treatment conclusion. The distribution of initial recurrence sites was
similar between the treatment groups. Neither the risk of relapse nor
the risk of death differed between the two groups. Of the six patients
with relapse or disease progression in the TACE plus HIFU group,
four patients had local progression and two had metastases. Twelve
patients treated with C5V chemotherapy had a relapse, nine had local
and distant progression, and three had metastases. At the last
observation, two of these patients were alive without evidence of disease.Table 4. Comparison of Disease Progression, Relapse, and Death between Treatment Regimens
C5V TACE Plus HIFU P *
Disease progression and relapse (n) 13 (n = 23) 5 (n = 12) .49
Death (n) 11 (n = 23) 4 (n = 12) .49
Death (n) without surgery 9 (n = 16) 4 (n = 8) 1.00
Post-surgery death 2 (n = 7) 0 (n = 4) .49
Postoperative complications 1 (n = 7) 0 (n = 4) 1.00
Disease progression 1 (n = 7) 0 (n = 4) 1.00
Post-surgery relapse 3 (n = 7) 0 (n = 4) .24
* Fisher exact test.Eighteen patients experienced disease progression or recurrence. There
were three deaths in the TACE plusHIFU group and nine deaths in the
chemotherapy group. Two patients treated with TACE plus HIFU
regimens were alive at the time of last contact after receiving additional
C5V chemotherapy, and 3 of the 12 patients initially treated with
chemotherapy were alive. Of the three deaths that occurred in the
TACE plus HIFU group, two patients died of cancer progression. One
death was attributed to complications from infection. There were nine
deaths in the C5V group.
Among the 11 patients treated with surgical resection, 5 (2 in the
C5V group and 3 in the TACE plus HIFU group) were alive with no
evidence of disease. Three patients experienced relapses (all from the
C5V group). Two of these patients had local progression, and one
patient had metastases. At the last observation, two of these three
patients were alive without evidence of disease, and one died of
disease progression. One child died of postoperative complications
(in the C5V group), and the data for two patients were missing
(in the C5V group).
Discussion
The current study was designed to compare the outcomes in children
treated with either the standard therapy for HB or a regimen
consisting of TACE plus HIFU. Our goal was to improve overall
surgical resection and decrease the long-term sequelae in children
with unresectable and metastatic HB. To our knowledge, this study
is the first report of such a large series of uniformly treated pediatric
HB patients.
Currently, advanced-stage disease requires more intensive chemo-
therapy treatments and increases the risk of an adverse outcome [21–23].
On the basis of the goal of decreasing total chemotherapy exposure, we
have favored HIFU in some patients for precise HB ablation. HIFU can
completely ablate target animal liver carcinomas and improve the survival
of animals with implanted liver tumors [14–18]. TACE is routinely
performed in cases of largeHB as repeated courses over a period of several
months before HIFU ablation [18]. Due to the variation between
populations, there is a large discrepancy between survival rates in
different studies [24–26]. It is preferential to assess the survival benefits of
a new treatment method within the same population. In this study, we
prospectively compared different treatment regimens in our institute.
Complete tumor resection remains the only realistic option for
obtaining a cure in childhood HB [27]. Thus, we chose the rate of
complete resection as the primary study end point. Our results
suggest that HIFU can improve the surgical resection rate. The
disease burden is greatly reduced following HIFU ablation, so the
surgical procedures were also easier to perform in these patients
compared with the C5V patients. Although there were no significant
differences between the two groups, 61% of patients in the
HIFU group had lesions larger than 10 cm in diameter (mean
diameter 11.3 cm), and the main branch of the portal vein was
invaded in 50% of patients. The lesion diameters in the
chemotherapy group were less than 10 cm (9.4 cm). Because parents
of patients with larger tumors preferred to select HIFU treatment,
some patients did not comply with the prescribed regimens, and some
patients refused further surgical treatment. There was a trend toward
improved survival in patients who received HIFU ablation, although
no clinically acceptable marginal difference was statistically proven
due to the limited number of patients. The 3-year survival rate for the
12 patients treated with TACE plus HIFU was 57.8%, which is
similar to that associated with other regimens used to treat patients
Translational Oncology Vol. 7, No. 6, 2014 Combination of HIFU and TACE for hepatoblastoma Chen et al. 793with advanced-stage disease [28,29]. Previous studies suggested that
relapses usually occur within the first 2 years after the end of HB
treatment. The current study used a 3-year follow-up and enabled
sufficient evaluation of the long-term efficacy of HIFU ablation and
comparison with other studies.
Although HIFU reduced tumor size, the relapse rate was similar to
that in patients treated with C5V during the follow-up period when
tumor resections were not performed. Therefore, HIFU provides
advantages of tumor excision but is not superior with respect to
overall survival compared with the C5V regimen. Therapeutic
strategies consisting of HIFU, surgery if operable, and four to six
cycles of adjuvant chemotherapy are recommended in patients with
HB. Importantly, the patients who did receive HIFU treatment had
positive responses to chemotherapy, which suggested that drug
resistance was not increased by HIFU administration. These results
also emphasize that the presence of lung metastases at diagnosis is not
a contraindication for HIFU. If effective chemotherapy is adminis-
tered, the lung lesions are completely cleared by chemotherapy and
metastasectomy (if needed).
Although the treatment regimens compared in the current study
were not significantly different with respect to survival outcome, there
were significant differences in the types of events and toxicities
associated with the two regimens. The main treatment toxicity was
hematological and included a profound neutropenia in most children
treated with C5V. Conversely, an extremely low rate of major
complications was observed in patients treated with HIFU ablation.
No toxic deaths or other events occurred more than 3 years after study
entry in patients treated with the HIFU regimen. This result suggests
a very small risk of toxicities in late follow-up in patients treated
with HIFU.
In summary, the results of this study suggest that the noninvasive
HIFU technique can be combined with TACE as a promising
approach for treating HB. The combination is effective, safe, and
feasible and may play an important role in the treatment of patients
with unresectable HB. We feel that this regimen should be included
in combination with front-line therapy in this patient population.
We acknowledge that these results were based on a small number of
patients. Thus, it will be necessary to perform large-scale multicenter
clinical trials in the future to determine the role of this modality in
unresectable and metastatic HB.
New Findings
1. Until now, TACE plus HIFU was first successfully attempted in
unresectable and metastatic hepatoblastoma in our institute.
2. Substantially significant improvement of the surgical resection
rate was observed in patients treated with TACE plus HIFU
ablation, concomitant with a low rate of major complications.
3. It exhibits rapid tumor size reduction within 6 months after
TACE plus HIFU ablation compared with C5V chemotherapy.
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